Impact of Review Paper

23 Jun 2005 16:00

LiDCO Group Plc23 June 2005 For Immediate Release 23rd June 2005 LiDCO GROUP PLC ("LiDCO" or "the Company") Modernising Care for Patients Undergoing Major Surgery 23rd June 2005: LiDCO Group plc (AIM: LID), the cardiovascular monitoringcompany, is pleased to announce that at the 4th Evidence Based Peri-OperativeMedicine Conference in London a review paper entitled "Modernising Care forPatients Undergoing Major Surgery: Improving Patient Outcomes and IncreasingClinical Efficiency*" was presented by the Improving Surgical Outcomes Group. The paper states: 1) improvements in post-operative assessment and preparation, peri-operativecare and post-operative support have provided an important reduction in themortality rate as well as decreasing the number and severity of complicationssuffered by patients following surgery and; 2) savings, in terms of ICU/HDU bed days per patient, were made as aconsequence. In conclusion the paper said that the resource is already available in hospitalsto modernise the treatment of surgical patients, reduce costs and improve theoutcomes from surgical intervention. Therefore the capital and running costs are'marginal in comparison with the potential savings.' Of significance for the use of LiDCO's technology the report concluded that 'forhemodynamic optimisation, the potential savings in terms of reduced hospitalstays have been estimated for an average NHS trust to be in the order of over £2million, based on a reduction in stays of 22-31% and taking into account capitaloutlay of £60,000 and running costs of £150,000.' Dr Terry O'Brien, LiDCO's Chief Executive, commented: "The Improving SurgicalOutcomes Group have clearly concluded that the NHS can significantly improvesurgical outcomes while reducing costs through the adoption of cost effectivemonitoring technologies such as the LiDCOplus Monitor. This new standard of careis both affordable and achievable and is a better use of the existing hospitalsresources." * A copy of the review will be available on LiDCO's website. For further information please contact: LiDCO Group PlcTerry O'Brien (CEO) terry@lidco.com 020 7749 1500Hugh McGarel-Groves (FD) hugh.mcgarel-groves@lidco.comBuchanan CommunicationsTim Anderson, Mary-Jane Johnson, James Strong 020 7466 5000Panmure GordonGrant Harrison 020 7459 3600Marcus Jackson Notes for Editors About LiDCO Plc LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier ofminimally invasive, computer-based hemodynamic monitoring equipment anddisposables used primarily for the management of critical care andcardiovascular risk hospital patients. Use of LiDCO's technology has been shownto significantly reduce the complications (particularly infections) and costsassociated with major surgery. The technology was invented in the Department ofApplied Physiology based at St Thomas' Hospital, London where the Companymaintains a research base. The Company's manufacturing facility is in Hoxton, London and its currentproducts are: • LiDCOplus and PulseCO monitors: computer-based platforms for displaying arange of real-time, continuous hemodynamic parameters including cardiac output,oxygen delivery and fluid volume; • LiDCO disposables: used in conjunction with the LiDCOplus Monitoraccurately determine cardiac output in a minimally-invasive manner. Distribution Network: The Company has now achieved registration of its products in 13 markets inEurope, the USA, Brazil and Japan. It sells direct to the NHS in the UK, andthrough a worldwide network of specialty critical care distributors. Background to the recently published clinical trial: Better than standard care -(EGDT) improves outcome in high risk surgery patients: The results of a major trial at St George's Hospital, London using LiDCO'sminimally invasive monitoring technology were presented during the 25thInternational Symposium on Intensive Care and Emergency Medicine in Brussels(21st to 25th March). The results have revealed the following: a) Savings in the cost of treating patients amounting to an average of £4,000per patient. Extrapolated nationally, this would equate to a saving of £500million per annum for the NHS b) The monetary saving (£248,000) - resulted from 640 hospital days saved for 62patients, an average of more than 10 bed days per patient c) The savings in cost and hospital days were associated with a significantreduction in medical complications (particularly infections - which were halved) through the use of LiDCO's minimally invasive technology to improve tissueoxygen levels following surgery. This information is provided by RNS The company news service from the London Stock Exchange